PTC Therapeutics
PTCT
183 hedge funds and large institutions have $2.71B invested in PTC Therapeutics in 2022 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 65 increasing their positions, 58 reducing their positions, and 18 closing their positions.
56% more call options, than puts
Call options by funds: $1.99M | Put options by funds: $1.28M
44% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 18
12% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 58
3% more funds holding
Funds holding: 178 → 183 (+5)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
2.23% less ownership
Funds ownership: 106.62% → 104.39% (-2.2%)
10% less capital invested
Capital invested by funds: $3B → $2.71B (-$297M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$81.6M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$38.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$14.7M |
| 4 |
JP Morgan Chase
New York
|
+$6.1M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$5.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$90.5M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$47M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$15M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14.1M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$12.6M |
PTCT Hedge Fund Activity: Q1 2022 in Review
183 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q1 2022, worth a combined $2.71B — down 9.9% from $3B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new PTCT positions and 18 closed out — a net gain of 8 holders — while 65 added to existing stakes and 58 trimmed.
The largest buyer was Armistice Capital, adding an estimated $81.6M. The largest seller was Bank of America, cutting an estimated $90.5M.
- 183 institutional investors held PTC Therapeutics (PTCT) as of Q1 2022, up from 178 in Q4 2021.
- Funds reported $2.71B of PTC Therapeutics stock for Q1 2022, down 9.9% quarter-over-quarter.
- 26 funds opened new PTC Therapeutics positions in Q1 2022 and 18 closed out, a net change of +8 holders.
- The largest PTC Therapeutics buyer in Q1 2022 was Armistice Capital, an estimated $81.6M added.
- The largest PTC Therapeutics seller in Q1 2022 was Bank of America, an estimated $90.5M sold.
Based on aggregated 13F filings for Q1 2022.